［1］Vincent JL, Gottin L. Type of fluid in severe sepsis and septic shock. Minerva Anestesiol, 2011, 77(12):1190-1196.
［2］Cochrane Injuries Grnup Albumin Reviewers. Human albumin administration in critically ill patients：systematic review of randnmised controlled trials. BMJ,1998,317(7153):235-240.
［3］Finfer S, Bellomo R, Boyee N, et al. A comparison of albmnin and saline for fluid resuscitation in the intensive care unit. N Engl J Med, 2004, 350(22)：2247-2256.
［4］SAFE Study Investigators, Finfer S, McEvoy S, et al. Impact of albumin compared to saline on organ function and mortality of patients with severe sepsis. Intensive Care Med, 2011, 37(1):86-96.
［5］Delaney AP, Dan A, McCaffrey J, et al. The role of albumin as a resuscitation fluid for patients with sepsis: a systematic review and meta-analysis. Crit Care Med, 2011, 39(2):386-391.
［6］Hartog CS, Bauer M, Reinhart K. The efficacy and safety of colloid resuscitation in the critically ill. Anesth Analg, 2011,112(1):156-164.
［7］Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med, 2008, 358(2):125-139.
［8］Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. N Engl J Med, 2012, 367(2):124-134.
［9］Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med, 2012, 367(20):1901-1911.
［10］Wise J. Boldt: the great pretender. BMJ, 2013, 346(7900): f1738.
［11］Zarychanski R, Abo-Setta AM, Turgeon AF, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA, 2013, 309(7):678-688.
［12］Haase N, Perner A, Hennings LI, et al. Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ, 2013, 346(7900):f839.
［13］Gattas DJ, Dan A, Myburgh J, et al. CHEST management Committee. Fluid resuscitation with 6% hydroxyethyl starch (130/0.4 and 130/0.42) in acutely ill patients: systematic review of effects on mortality and treatment with renal replacement therapy. Intensive Care Med, 2013, 39(4):558-568.
［14］Patel A, Waheed U, Brett SJ. Randomised trials of 6% tetrastarch (hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: systematic review and meta-analysis. Intensive Care Med, 2013, 39(5):811-822.
［15］Mutter TC, Ruth CA, Dart AB. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database Syst Rev, 2013, 7:CD007594.
［16］Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med, 2013,41(2):580-637.
［17］Reinhart K, Perner A, Sprung CL, et al. Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. Intensive Care Med, 2012, 38(3):368-383.
［18］Guidet B. Hydroxyethyl starch or saline in intensive care. N Engl J Med, 2013, 368(8):774.
［19］Phillips DP,Kaynar AM,Kellum JA,et al.Crystalloids vs. colloids: KO at the twelfth round? Crit Care,2013,17（3）:319.
［20］Guidet B, Martinet O, Boulain T, at al. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: the CRYSTMAS study. Crit Care,2012,16(3):R94.
［21］Bark BP, Persson J, Grnde PO. Importance of the infusion rate for the plasma expanding effect of 5% albumin, 6% HES 130/0.4, 4% gelatin, and 0.9% NaCl in the septic rat. Crit Care Med, 2013, 41(3):857-866.
［22］Dolecek M, Svoboda P, Kantotová I, et al. Therapeutic influence of 20% albumin versus 6% hydroxyethylstarch on extravascular lung water in septic patients: a randomized controlled trial. Hepatogastroenterology, 2009, 56(96):1622-1628.
［23］Rioux JP, Lessard M, De Bortoli B, et al. Pentastarch 10% (250 kDa/0.45) is an independent risk factor of acute kidney injury following cardiac surgery. Crit Care Med, 2009, 37（4）:1293-1298.
